Market Intelligence: Immune Senescence, NK Cell Biology, HNK-1 Epitope Therapeutics, and Glyco-Immunology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for B3GAT1 drug discovery:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (ECD-Fc / Catalytic Domain) | B3GAT1 ECD-Fc or Catalytic Domain recombinant protein. High purity (>95%), Endotoxin <1EU/ug. HEK293 expressed for native glycosylation. Sequence verified by mass spectrometry. | View B3GAT1 Products |
| Gene Delivery | B3GAT1 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines preserving Golgi topology. High titer (>10^8 TU/mL). | View B3GAT1 Products |
| Benchmark Ab | Anti-B3GAT1/CD57 (Clone HNK-1 Sequence) recombinant antibody. Positive control for flow cytometry. Carbohydrate epitope verified. | View B3GAT1 Products |
| Validator | B3GAT1 siRNA Set. For knockdown verification and target engagement correlation. | View B3GAT1 Products |
| Pathway Partner | B3GNT2 (Glucuronosyl-N-acetylglucosaminyl). Cooperative enzyme in HNK-1 epitope synthesis. | View B3GNT2 Products |
| Carrier Protein | NCAM1 (CD56). Primary carrier of HNK-1 epitope. Critical for cell adhesion assays. | View NCAM1 Products |
| Competing Enzyme | ST3GAL4 (ST3Gal IV). Sialyltransferase competing for same substrate. For selectivity screening. | View ST3GAL4 Products |
| Upstream Partner | B3GALT2. Synergistic HNK-1 synthesis pathway enzyme; upstream galactosyltransferase partner. | View B3GALT2 Products |
| Related Target (Checkpoint) | PDCD1 (PD-1). Synergistic pathway in T-cell exhaustion and immune evasion. | View PDCD1 Products |
| Related Target (Senescence) | KLRG1. Co-expressed marker for terminally differentiated, senescent lymphocytes. | View KLRG1 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Glycosylation & Golgi Conformation | HEK293-expressed antigen and Lentivirus for stable cell lines preserving native topology and post-translational modifications. |
| Paralog Selectivity (B3GAT2/3) & Cross-species Translation | Human/Mouse/Cyno ortholog proteins available with >95% purity; sequence verified by mass spectrometry. |
| Activity vs Epitope Discrimination (HNK-1 carbohydrate vs B3GAT1 protein) | Defined HNK-1 monoclonal with sequenced variable regions; siRNA for knockdown confirmation of epitope specificity. |
| Lack of Reliable Controls | Clinical Benchmark Anti-CD57 Antibody (HNK-1 clone) and validated siRNA included. |
| High Background / False Positives in Assays | Endotoxin-controlled (<1 EU/µg) proteins; validated siRNA sets for target-specificity checks. |
Live B3GAT1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for B3GAT1 (CD57) therapeutics and diagnostics is intensifying. Historically utilized as a definitive biomarker for terminally differentiated and senescent T-cells and NK cells, B3GAT1 is now gaining traction as a functional target in the tumor microenvironment (TME), aging-related diseases, and autoimmunity. The HNK-1 carbohydrate epitope, synthesized by B3GAT1, is a target for selective depletion of senescent immune populations. First-generation anti-CD57 ADCs are entering preclinical phases for neuroblastoma and small cell lung cancer (SCLC). Concurrently, small-molecule inhibitors targeting the B3GAT1 catalytic domain are being explored for multiple sclerosis, autoimmune diseases, and neural regeneration. CAR-T manufacturing processes increasingly leverage B3GAT1 profiling to screen out exhausted phenotypes and enhance long-term persistence. The next wave of R&D emphasizes the critical distinction between targeting the HNK-1 carbohydrate epitope (enzymatic product) versus the B3GAT1 protein backbone.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Diagnostic/Sorting mAbs | Miltenyi Biotec, BD Biosciences, BioLegend, Thermo Fisher | CAR-T Manufacturing, Immunophenotyping, T-cell Profiling | High-Affinity Binding Assay (HEK293-expressed antigen) |
| ADC (Anti-CD57/Senolytic) | Emerging Biotechs, University Consortia | Refractory Solid Tumors, Neuroblastoma, SCLC, Aging | Internalization Assay (Stable B3GAT1-expressing cell lines) |
| Bispecifics | Undisclosed Early R&D | Immune Modulation | Heterodimer Validation (Cross-reactive Abs, controlled endotoxin) |
| Small Molecule Inhibitor / Enzyme Inhibitor | Academic/Biotech Consortia | Neurological Disorders, TME, Multiple Sclerosis, Autoimmune | Enzymatic Selectivity Assay (High-purity catalytic domain) |
| Cell Therapy Modulation / Exclusion | CAR-T/NK Therapy Innovators | ALL, NHL, Hematologic Malignancies | Flow Cytometry Differentiation Panel (Benchmark Abs & siRNA) |
Related Targets for Combination Strategies
- View PDCD1 Products (PD-1): Classic marker of T-cell exhaustion; often co-analyzed with CD57 for combination therapy strategies.
- View KLRG1 Products: Another well-characterized inhibitory receptor on terminally differentiated NK and T cells; parallel target for senolytic drug development.
- View B3GNT2 Products: Upstream enzyme in HNK-1 synthesis; dual targeting may completely block epitope formation.
- View NCAM1 Products (CD56): Primary carrier of HNK-1 epitope; critical for cell adhesion and antigen density assessment.
- View ST3GAL4 Products: Competing sialyltransferase; crucial for selectivity screening of enzymatic inhibitors.
- View B3GALT2 Products: Additional galactosyltransferase partner in HNK-1 pathway.